Biomarker development for PCOS diagnosis

Abstract

Polycystic Ovary Syndrome, most commonly known as PCOS, is a condition that affects at least 6 million women of reproductive age in the United States alone. Approximately 10% of women worldwide are affected by PCOS as it is the number one cause of female infertility. Diagnosis of PCOS is not a process that has been fully coagulated as many of the symptoms overlap with many other conditions. Biomarker development to diagnose PCOS during the earlier stages is critical to making advancements in the field as earlier detection means more time to treat the symptoms and possibly find a treatment.